We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Stock Moves -0.07%: What You Should Know
Read MoreHide Full Article
Abbott (ABT - Free Report) ended the recent trading session at $135.87, demonstrating a -0.07% swing from the preceding day's closing price. This change was narrower than the S&P 500's 1.59% loss on the day. Meanwhile, the Dow experienced a drop of 0.45%, and the technology-dominated Nasdaq saw a decrease of 2.78%.
Shares of the maker of infant formula, medical devices and drugs witnessed a gain of 6.34% over the previous month, beating the performance of the Medical sector with its gain of 1.73% and the S&P 500's loss of 2.23%.
The upcoming earnings release of Abbott will be of great interest to investors. On that day, Abbott is projected to report earnings of $1.07 per share, which would represent year-over-year growth of 9.18%. Our most recent consensus estimate is calling for quarterly revenue of $10.39 billion, up 4.28% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.15 per share and revenue of $44.35 billion, indicating changes of +10.28% and +5.73%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Abbott. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Abbott is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Abbott is presently trading at a Forward P/E ratio of 26.43. This denotes a premium relative to the industry's average Forward P/E of 20.
It's also important to note that ABT currently trades at a PEG ratio of 2.54. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical - Products industry stood at 2.07 at the close of the market yesterday.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 129, this industry ranks in the bottom 49% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Stock Moves -0.07%: What You Should Know
Abbott (ABT - Free Report) ended the recent trading session at $135.87, demonstrating a -0.07% swing from the preceding day's closing price. This change was narrower than the S&P 500's 1.59% loss on the day. Meanwhile, the Dow experienced a drop of 0.45%, and the technology-dominated Nasdaq saw a decrease of 2.78%.
Shares of the maker of infant formula, medical devices and drugs witnessed a gain of 6.34% over the previous month, beating the performance of the Medical sector with its gain of 1.73% and the S&P 500's loss of 2.23%.
The upcoming earnings release of Abbott will be of great interest to investors. On that day, Abbott is projected to report earnings of $1.07 per share, which would represent year-over-year growth of 9.18%. Our most recent consensus estimate is calling for quarterly revenue of $10.39 billion, up 4.28% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.15 per share and revenue of $44.35 billion, indicating changes of +10.28% and +5.73%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Abbott. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Abbott is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Abbott is presently trading at a Forward P/E ratio of 26.43. This denotes a premium relative to the industry's average Forward P/E of 20.
It's also important to note that ABT currently trades at a PEG ratio of 2.54. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical - Products industry stood at 2.07 at the close of the market yesterday.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 129, this industry ranks in the bottom 49% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.